Diadema Partners’s Rigel Pharmaceuticals RIGL Stock Holding History

Diadema Partners’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-30,000	Closed	-$1.28M	–	195
2025 Q4	$1.28M	Buy	+30,000	New	+$1.13M	0.22%	84

Other funds holding RIGL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Diadema Partners's RIGL Position: Q1 2026 in Review

Diadema Partners sold out of Rigel Pharmaceuticals (RIGL) in Q1 2026, closing a stake of 30,000 shares — an estimated $1.28M sold.

Diadema Partners first reported a position in RIGL in Q4 2025 and held it in 1 quarter. The position peaked at $1.28M in Q4 2025. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

Diadema Partners reported no remaining Rigel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Diadema Partners sold 30,000 Rigel Pharmaceuticals shares in Q1 2026, an estimated $1.28M.
Diadema Partners first reported a position in Rigel Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Diadema Partners's Rigel Pharmaceuticals position peaked at $1.28M in Q4 2025.
159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.